The CARE Program: An Initiative of Patient-Focused Drug Development for Rare Diseases by NMPA

Area of Science:

• Pharmacology
• Patient Advocacy
• Regulatory Science

Background:

• Patient-focused drug development emphasizes multi-stakeholder collaboration and patient input.
• Integrating patient perspectives is crucial for understanding rare diseases and patient needs.
• This approach enhances the precision and efficiency of rare disease drug development.

Purpose of the Study:

• To guide pharmaceutical companies in incorporating rare disease patient perspectives throughout drug development.
• To improve the scientific rigor and standardization of integrating patient voices in rare disease clinical development.
• To accumulate experience for future regulatory work and drug development efforts in rare diseases.

Main Methods:

• The Center for Drug Evaluation, NMPA launched the pilot "Care Program" focusing on rare diseases.
• The program guides pharmaceutical companies to integrate patient perspectives.
• Focuses on the entire drug development process.

Main Results:

• The "Care Program" aims to enhance the precision and efficiency of rare disease drug development.
• Expected to improve the scientific rigor and standardization of integrating patient voices.
• Will accumulate valuable experience for future regulatory work and drug development.

Conclusions:

• Implementing patient-focused drug development is an effective approach for rare diseases.
• The "Care Program" is a significant initiative to standardize patient input in rare disease drug development.
• This pilot program is expected to yield valuable insights for regulatory bodies and pharmaceutical companies.